Bengt Erik Haug

Title: Innovations by Bengt Erik Haug

Introduction

Bengt Erik Haug is a notable inventor based in Tromsø, Norway. He has made significant contributions to the field of therapeutic peptides, particularly in the development of anti-tumor agents. With a total of four patents to his name, Haug's work is at the forefront of medical innovation.

Latest Patents

Haug's latest patents include a Nonapeptide with anti-tumor activity. This invention relates to peptides or peptide-like molecules and their uses in therapy, specifically as anti-tumor agents. Another significant patent is a Method of treating tumors, which provides a method of treating tumors by administering to a human or animal patient an effective amount of a molecule of 2 to 4 amino acids or equivalent subunits in length. This molecule incorporates a bulky and lipophilic group comprising at least 13 non-hydrogen atoms and contains no more than 2 polar functional groups. The bulky and lipophilic group incorporates one or more closed rings of 5 or more non-hydrogen atoms, and the molecule further has at least two more cationic than anionic moieties.

Career Highlights

Haug is currently associated with Lytix Biopharma AS, where he continues to innovate in the field of biopharmaceuticals. His work has garnered attention for its potential impact on cancer treatment and therapy.

Collaborations

Some of Haug's notable coworkers include John Sigurd Svendsen and Istvan Marko, who contribute to the collaborative efforts in research and development within the company.

Conclusion

Bengt Erik Haug's contributions to the field of therapeutic peptides and anti-tumor agents highlight his role as a significant inventor in modern medicine. His innovative patents pave the way for advancements in cancer treatment.